Lightnews — Scholar-powered news

Myeloma Society @myeloma-society.bsky.social · 13h

🚨Register now! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! ➡️bit.ly/4poxPuF

Myeloma Society @myeloma-society.bsky.social · 1d

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

1 2

Myeloma Society @myeloma-society.bsky.social · 2d

There is still time to register for our complimentary webinars on Relapsed/Refractory Multiple Myeloma!
📅 Oct 8 | 6–7:30 PM ET (East Coast)
📅 Oct 15 | 6–7:30 PM PT (West Coast)
Register: bit.ly/4659Tov

1 2

Myeloma Society @myeloma-society.bsky.social · 5d

Check out IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community.

Listen, download, and share here ➡️ https://rb.gy/tw8r1v

2

Myeloma Society @myeloma-society.bsky.social · 6d

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement.
📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

1

Myeloma Society @myeloma-society.bsky.social · 7d

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

3

Myeloma Society @myeloma-society.bsky.social · 8d

🚨Register now! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! ➡️bit.ly/4poxPuF

1

Myeloma Society @myeloma-society.bsky.social · 9d

Join us for a complimentary IMS Webinar on Relapsed/Refractory Multiple Myeloma!
📅 Oct 8 | 6–7:30 PM ET (East Coast)
📅 Oct 15 | 6–7:30 PM PT (West Coast)
Register: bit.ly/4659Tov

1

Myeloma Society @myeloma-society.bsky.social · 12d

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement.
📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

1

Myeloma Society @myeloma-society.bsky.social · 13d

🚨We are just under 6 weeks away! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! bit.ly/4poxPuF

1

Myeloma Society @myeloma-society.bsky.social · 18d

Don't forget, you can still access #IMS25 meeting content. If you registered for either in-person or virtual this year, log in to the virtual platform to review all recorded sessions.

1 3

Myeloma Society @myeloma-society.bsky.social · 18d

Thank you to everyone who joined #IMS25, both in person and virtually. Save the date for next year's conference, taking place September 23-26 in Glasgow, Scotland. We look forward to seeing you in 2026!

5

Myeloma Society @myeloma-society.bsky.social · 18d

Day 4 highlights from the 22nd Annual IMS Meeting! #IMS25

2

Myeloma Society @myeloma-society.bsky.social · 18d

Three myeloma experts made engaging & persuasive arguments for the supremacy of ADCs, bispecifics, and CAR-Ts for treating MM. No clear winner in this dynamic debate but having these options counts as a win for the race to cure myeloma! #IMS25

3

Myeloma Society @myeloma-society.bsky.social · 18d

Xavier Leleu, MD, PhD, gave a moving tribute to Frank Bridoux, MD, PhD, friend & colleague at the University Hospital Poitiers. Dr. Bridoux’s expertise included cast nephropathy & glomerulopathies, and seminal contributions in MGRS/MGCS. #IMS25

1 1

Myeloma Society @myeloma-society.bsky.social · 18d

✨Join us in Hall FG for the conclusion of #IMS25!
12:00 PM ➡️ Highlights of the 2025 Annual Meeting
1:00 PM ➡️ Debate on ADCs, Bispecifics or CART
2:00 PM ➡️ Closing Ceremony

Myeloma Society @myeloma-society.bsky.social · 18d

Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25

1 4

Myeloma Society @myeloma-society.bsky.social · 18d

Coming up at 10:00 AM in Hall FG: Future Targets and New Modalities of Therapy #IMS25

Myeloma Society @myeloma-society.bsky.social · 18d

Don’t miss the upcoming abstract sessions at 9:00 AM:
📍Room 701 → Abstract Session 9
📍Room 718 → Abstract Session 10

1

Myeloma Society @myeloma-society.bsky.social · 18d

Congratulations to this year's Young Investigator Award recipients at #IMS25.

1 3

Myeloma Society @myeloma-society.bsky.social · 18d

It’s time for the morning abstracts! #IMS25
📍 Room 701 → Abstract Session 7
📍 Room 718 → Abstract Session 8

1

Myeloma Society @myeloma-society.bsky.social · 18d

It’s the final day of #IMS25! Check the program for today’s highlights and don’t miss the Debate on ADCs, Bispecifics or CART later today! bit.ly/3K8T4QU

1

Myeloma Society @myeloma-society.bsky.social · 18d

Another inspiring day of research and community at #IMS25

1

Myeloma Society @myeloma-society.bsky.social · 19d

Day 3 highlights from the 22nd Annual IMS Meeting!
#IMS25

1

Myeloma Society @myeloma-society.bsky.social · 19d

A multi-stakeholder panel discussed a recent EMA-IMS-EHA survey on the attitudes of clinicians and regulators on MRD as an efficacy endpoint in myeloma, nuances of US & EU perspectives, & transplant-eligibility for patient stratification. #IMS25

1 3